Logo image of LQDA

LIQUIDIA CORP (LQDA) Stock Fundamental Analysis

NASDAQ:LQDA - Nasdaq - US53635D2027 - Common Stock - Currency: USD

15.535  -0.59 (-3.63%)

After market: 15.535 0 (0%)

Fundamental Rating

2

LQDA gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 198 industry peers in the Pharmaceuticals industry. LQDA may be in some trouble as it scores bad on both profitability and health. LQDA is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

LQDA had negative earnings in the past year.
In the past year LQDA has reported a negative cash flow from operations.
In the past 5 years LQDA always reported negative net income.
In the past 5 years LQDA always reported negative operating cash flow.
LQDA Yearly Net Income VS EBIT VS OCF VS FCFLQDA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M -80M -100M

1.2 Ratios

LQDA has a worse Return On Assets (-56.62%) than 64.14% of its industry peers.
Looking at the Return On Equity, with a value of -168.74%, LQDA is doing worse than 65.15% of the companies in the same industry.
Industry RankSector Rank
ROA -56.62%
ROE -168.74%
ROIC N/A
ROA(3y)-51.66%
ROA(5y)-50.39%
ROE(3y)-127.25%
ROE(5y)-103.75%
ROIC(3y)N/A
ROIC(5y)N/A
LQDA Yearly ROA, ROE, ROICLQDA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200 -200

1.3 Margins

LQDA has a better Gross Margin (58.00%) than 66.67% of its industry peers.
LQDA's Gross Margin has declined in the last couple of years.
The Profit Margin and Operating Margin are not available for LQDA so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 58%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-8.82%
GM growth 5Y-8.41%
LQDA Yearly Profit, Operating, Gross MarginsLQDA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -2K -4K -6K -8K

More info and screens

3

2. Health

2.1 Basic Checks

LQDA does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for LQDA has been increased compared to 1 year ago.
LQDA has more shares outstanding than it did 5 years ago.
The debt/assets ratio for LQDA is higher compared to a year ago.
LQDA Yearly Shares OutstandingLQDA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M
LQDA Yearly Total Debt VS Total AssetsLQDA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

2.2 Solvency

Based on the Altman-Z score of 1.07, we must say that LQDA is in the distress zone and has some risk of bankruptcy.
LQDA has a better Altman-Z score (1.07) than 62.63% of its industry peers.
LQDA has a Debt/Equity ratio of 1.26. This is a high value indicating a heavy dependency on external financing.
With a Debt to Equity ratio value of 1.26, LQDA is not doing good in the industry: 72.73% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity 1.26
Debt/FCF N/A
Altman-Z 1.07
ROIC/WACCN/A
WACC9.7%
LQDA Yearly LT Debt VS Equity VS FCFLQDA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M -100M

2.3 Liquidity

A Current Ratio of 4.43 indicates that LQDA has no problem at all paying its short term obligations.
LQDA's Current ratio of 4.43 is fine compared to the rest of the industry. LQDA outperforms 68.18% of its industry peers.
A Quick Ratio of 4.42 indicates that LQDA has no problem at all paying its short term obligations.
With a decent Quick ratio value of 4.42, LQDA is doing good in the industry, outperforming 70.20% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 4.43
Quick Ratio 4.42
LQDA Yearly Current Assets VS Current LiabilitesLQDA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

More info and screens

5

3. Growth

3.1 Past

LQDA shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -39.17%.
Looking at the last year, LQDA shows a very negative growth in Revenue. The Revenue has decreased by -19.98% in the last year.
The Revenue has been growing by 11.64% on average over the past years. This is quite good.
EPS 1Y (TTM)-39.17%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-9.52%
Revenue 1Y (TTM)-19.98%
Revenue growth 3Y2.89%
Revenue growth 5Y11.64%
Sales Q2Q%-35.62%

3.2 Future

The Earnings Per Share is expected to grow by 26.02% on average over the next years. This is a very strong growth
LQDA is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 94.86% yearly.
EPS Next Y3.99%
EPS Next 2Y32.93%
EPS Next 3Y32.8%
EPS Next 5Y26.02%
Revenue Next Year174.73%
Revenue Next 2Y206.99%
Revenue Next 3Y157.08%
Revenue Next 5Y94.86%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
LQDA Yearly Revenue VS EstimatesLQDA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M 800M
LQDA Yearly EPS VS EstimatesLQDA Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 -2 -4

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

LQDA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for LQDA. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
LQDA Price Earnings VS Forward Price EarningsLQDA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
LQDA Per share dataLQDA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 -1 -1.5

4.3 Compensation for Growth

LQDA's earnings are expected to grow with 32.80% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y32.93%
EPS Next 3Y32.8%

More info and screens

0

5. Dividend

5.1 Amount

LQDA does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

LIQUIDIA CORP

NASDAQ:LQDA (5/6/2025, 8:21:53 PM)

After market: 15.535 0 (0%)

15.535

-0.59 (-3.63%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)03-19 2025-03-19/bmo
Earnings (Next)05-08 2025-05-08/amc
Inst Owners61.89%
Inst Owner Change-0.08%
Ins Owners4.02%
Ins Owner Change2.69%
Market Cap1.33B
Analysts85
Price Target27.31 (75.8%)
Short Float %18.47%
Short Ratio13.31
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)0.39%
Min EPS beat(2)-20.44%
Max EPS beat(2)21.21%
EPS beat(4)1
Avg EPS beat(4)-17.98%
Min EPS beat(4)-66.65%
Max EPS beat(4)21.21%
EPS beat(8)1
Avg EPS beat(8)-35.22%
EPS beat(12)4
Avg EPS beat(12)-19.11%
EPS beat(16)6
Avg EPS beat(16)-20.24%
Revenue beat(2)1
Avg Revenue beat(2)-16.84%
Min Revenue beat(2)-37.8%
Max Revenue beat(2)4.12%
Revenue beat(4)1
Avg Revenue beat(4)-32.33%
Min Revenue beat(4)-62.04%
Max Revenue beat(4)4.12%
Revenue beat(8)3
Avg Revenue beat(8)-16.85%
Revenue beat(12)6
Avg Revenue beat(12)-7.37%
Revenue beat(16)10
Avg Revenue beat(16)16.8%
PT rev (1m)5.7%
PT rev (3m)5.84%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0.33%
EPS NY rev (1m)0%
EPS NY rev (3m)-8.91%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-11.5%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-11.72%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 94.85
P/FCF N/A
P/OCF N/A
P/B 17.18
P/tB 18.91
EV/EBITDA N/A
EPS(TTM)-1.67
EYN/A
EPS(NY)-1.6
Fwd EYN/A
FCF(TTM)-1.19
FCFYN/A
OCF(TTM)-1.09
OCFYN/A
SpS0.16
BVpS0.9
TBVpS0.82
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -56.62%
ROE -168.74%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 58%
FCFM N/A
ROA(3y)-51.66%
ROA(5y)-50.39%
ROE(3y)-127.25%
ROE(5y)-103.75%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-8.82%
GM growth 5Y-8.41%
F-Score2
Asset Turnover0.06
Health
Industry RankSector Rank
Debt/Equity 1.26
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 384.57%
Cap/Sales 60.37%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.43
Quick Ratio 4.42
Altman-Z 1.07
F-Score2
WACC9.7%
ROIC/WACCN/A
Cap/Depr(3y)306.37%
Cap/Depr(5y)189%
Cap/Sales(3y)42.88%
Cap/Sales(5y)46.17%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-39.17%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-9.52%
EPS Next Y3.99%
EPS Next 2Y32.93%
EPS Next 3Y32.8%
EPS Next 5Y26.02%
Revenue 1Y (TTM)-19.98%
Revenue growth 3Y2.89%
Revenue growth 5Y11.64%
Sales Q2Q%-35.62%
Revenue Next Year174.73%
Revenue Next 2Y206.99%
Revenue Next 3Y157.08%
Revenue Next 5Y94.86%
EBIT growth 1Y-65.28%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year18.72%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-92.74%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-124.77%
OCF growth 3YN/A
OCF growth 5YN/A